 |
- The groundbreaking display projects critical driving information across the entire width of the windshield, offering a panoramic and immersive experience that spans from the driver's seat to the passenger's seat.
- Hyundai Mobis will also present its suite of human-centric technologies at CES 2025, including adaptive interior lighting and M.Brain, an advanced brainwave-based system.
SEOUL, South Korea, Dec. 12, 2024 /PRNewswire/ -- Hyundai Mobis, a leading global automotive supplier, will unveil its vision for the future of mobility at CES 2025, taking place at the Las Vegas Convention Center from January 7-10, 2025.
At CES, the company will unveil its Holographic Windshield Display, a groundbreaking innovation that enhances driving visibility through augmented reality. This first-of-its-kind display projects critical driving information—such as navigation, infotainment, and safety alerts—across the entire width of the front windshield. The result is a panoramic and immersive experience that seamlessly spans from the driver's seat to the passenger's seat.
Co-developed with the leading German optics company ZEISS, the display will be featured in Kia's electric vehicle, the EV9, exclusively for its unveiling at CES. By integrating specialized optical film, the system provides easy access to key information while maintaining an open, spacious feel and improving overall driving safety. Hyundai Mobis plans to begin mass production of this advanced technology as early as 2027.
Under the theme "Beyond and More," Hyundai Mobis will showcase a unique user experience at CES through its "Human Tech" initiative—a suite of technologies designed to bridge the gap between people and technology while enhancing safety and convenience with seamless, adaptive connections. Alongside the holographic windshield display, the company will unveil a human-centric interior lighting system that intelligently adapts to user needs and M.Brain, an advanced brainwave-based system that monitors and addresses driver distractions.
Hyundai Mobis will unveil its Human-Centric Interior Lighting technology, an adaptive lighting solution designed to adjust to the user's mood and environment. This innovative system offers 32 situational modes, including features to reduce driver stress, alleviate motion sickness, prevent dismounting hazards, and even provide UV-C sterilization. Visitors to the Hyundai Mobis booth can experience firsthand how this advanced lighting technology dynamically responds to biological rhythms, health conditions, and the vehicle's surroundings.
Another standout innovation is M.Brain, Hyundai Mobis' flagship brainwave-based technology. This advanced system monitors driver focus in real-time by analyzing brainwave data, providing alerts during states of drowsiness or inattention. Live demonstrations at CES will give visitors the opportunity to see M.Brain in action and explore its potential to enhance driver safety.
CES 2025 will mark Hyundai Mobis' tenth consecutive appearance at the world's largest tech show. Over the years, the company has consistently highlighted groundbreaking mobility innovations and production-ready technologies. At CES 2025, Hyundai Mobis will reaffirm its position as a leader in shaping the future of mobility.
About Mobis
Hyundai Mobis is the global no. 6 automotive supplier, headquartered in Seoul, Korea. Mobis has outstanding expertise in sensors, sensor fusion in ECUs and software development for safety control. The company's products also include various components for electrification, brakes, chassis and suspension, steering, airbags, lighting, and automotive electronics. Mobis operates its R&D headquarters in Korea, with four technology centers in the United States, Germany, China and India. For more information, please visit the website at http://www.mobis.com
Media Contact
Choon Kee Hwang
+82-2-2018-5519
ckhwang@mobis.com
Myong Sun Song
+82-2-2018-6535
sms@mobis.com
- The groundbreaking display projects critical driving information across the entire width of the windshield, offering a panoramic and immersive experience that spans from the driver's seat to the passenger's seat.
- Hyundai Mobis will also present its suite of human-centric technologies at CES 2025, including adaptive interior lighting and M.Brain, an advanced brainwave-based system.
SEOUL, South Korea, Dec. 12, 2024 /PRNewswire/ -- Hyundai Mobis, a leading global automotive supplier, will unveil its vision for the future of mobility at CES 2025, taking place at the Las Vegas Convention Center from January 7-10, 2025.
At CES, the company will unveil its Holographic Windshield Display, a groundbreaking innovation that enhances driving visibility through augmented reality. This first-of-its-kind display projects critical driving information—such as navigation, infotainment, and safety alerts—across the entire width of the front windshield. The result is a panoramic and immersive experience that seamlessly spans from the driver's seat to the passenger's seat.
Co-developed with the leading German optics company ZEISS, the display will be featured in Kia's electric vehicle, the EV9, exclusively for its unveiling at CES. By integrating specialized optical film, the system provides easy access to key information while maintaining an open, spacious feel and improving overall driving safety. Hyundai Mobis plans to begin mass production of this advanced technology as early as 2027.
Under the theme "Beyond and More," Hyundai Mobis will showcase a unique user experience at CES through its "Human Tech" initiative—a suite of technologies designed to bridge the gap between people and technology while enhancing safety and convenience with seamless, adaptive connections. Alongside the holographic windshield display, the company will unveil a human-centric interior lighting system that intelligently adapts to user needs and M.Brain, an advanced brainwave-based system that monitors and addresses driver distractions.
Hyundai Mobis will unveil its Human-Centric Interior Lighting technology, an adaptive lighting solution designed to adjust to the user's mood and environment. This innovative system offers 32 situational modes, including features to reduce driver stress, alleviate motion sickness, prevent dismounting hazards, and even provide UV-C sterilization. Visitors to the Hyundai Mobis booth can experience firsthand how this advanced lighting technology dynamically responds to biological rhythms, health conditions, and the vehicle's surroundings.
Another standout innovation is M.Brain, Hyundai Mobis' flagship brainwave-based technology. This advanced system monitors driver focus in real-time by analyzing brainwave data, providing alerts during states of drowsiness or inattention. Live demonstrations at CES will give visitors the opportunity to see M.Brain in action and explore its potential to enhance driver safety.
CES 2025 will mark Hyundai Mobis' tenth consecutive appearance at the world's largest tech show. Over the years, the company has consistently highlighted groundbreaking mobility innovations and production-ready technologies. At CES 2025, Hyundai Mobis will reaffirm its position as a leader in shaping the future of mobility.
About Mobis
Hyundai Mobis is the global no. 6 automotive supplier, headquartered in Seoul, Korea. Mobis has outstanding expertise in sensors, sensor fusion in ECUs and software development for safety control. The company's products also include various components for electrification, brakes, chassis and suspension, steering, airbags, lighting, and automotive electronics. Mobis operates its R&D headquarters in Korea, with four technology centers in the United States, Germany, China and India. For more information, please visit the website at http://www.mobis.com
Media Contact
Choon Kee Hwang
+82-2-2018-5519
ckhwang@mobis.com
Myong Sun Song
+82-2-2018-6535
sms@mobis.com
** The press release content is from PR Newswire. Bastille Post is not involved in its creation. **
Hyundai Mobis to Showcase World's First Full-Windshield Holographic Display at CES 2025
|
Accomplished medical research leader will oversee NCCN programs to advance clinical trials and improve the quality, effectiveness, and accessibility of cancer care.
PLYMOUTH MEETING, Pa., April 9, 2026 /PRNewswire/ -- Today, the National Comprehensive Cancer Network® (NCCN®)—an alliance of leading cancer centers devoted to patient care, research, and education—announced the selection of Nancy L. Lewis, MD, MBS, FACP, as new Chief Scientific Officer (CSO).
Dr. Lewis is an experienced biomedical researcher with expertise in clinical trials for treating solid tumors and hematologic malignancies. She most recently served as Senior Clinical Program Leader for Novartis Pharmaceuticals, after several years as an Associate Professor for various prestigious academic cancer centers. She holds degrees from Penn State University, Temple University School of Medicine, and Rutgers University. Dr. Lewis completed residency at the University of Rochester and Fellowship at Fox Chase Cancer Center—one of NCCN's founding Member Institutions.
"This is a pivotal time for cancer research; there are many successes to build on yet so much still to do. Dr. Lewis is the perfect person to oversee the work we do to foster innovation and knowledge discovery that improves the lives of people with cancer," said Crystal S. Denlinger, MD, CEO, NCCN. "She will be an important asset to our leadership team as she helps us ensure our research and clinical programs continue to advance outcomes in oncology around the world."
Dr. Lewis has previously been honored with awards from some of the foremost cancer organizations across the country, including the American Association for Cancer Research (AACR), The American Society of Clinical Oncology (ASCO), and the American Cancer Society (ACS).
As CSO, Dr. Lewis will assist in the NCCN Oncology Research Program (ORP) as well as key aspects of the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) and NCCN Guidelines for Patients®. She will have oversight of the NCCN Biomarkers Compendium®; NCCN Radiation Therapy Compendium™, and NCCN Imaging Appropriate Use Criteria™. Dr. Lewis will also assist with NCCN's Continuing Medical Education Program and with relevant global and policy initiatives.
"I am thrilled to join the National Comprehensive Cancer Network and contribute to its extraordinary legacy of advancing high‑quality cancer care," said Dr. Lewis. "I look forward to working with NCCN's exceptional collaborators to tackle emerging challenges and drive innovative solutions that improve the lives of patients everywhere."
Dr. Lewis will succeed Dr. Denlinger who previously held the position of CSO before becoming CEO for the organization. Dr. Lewis will assume her new role in May 2026.
About the National Comprehensive Cancer Network
The National Comprehensive Cancer Network® (NCCN®) is a not-for-profit alliance of leading cancer centers devoted to patient care, research, and education. NCCN is dedicated to defining and advancing quality, effective, equitable, and accessible cancer care and prevention so all people can live better lives. The NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) provide transparent, evidence-based, expert consensus-driven recommendations for cancer treatment, prevention, and supportive services; they are the recognized standard for clinical direction and policy in cancer management and the most thorough and frequently-updated clinical practice guidelines available in any area of medicine. The NCCN Guidelines for Patients® provide expert cancer treatment information to inform and empower patients and caregivers, through support from the NCCN Foundation®. NCCN also advances continuing education, global initiatives, policy, and research collaboration and publication in oncology. Visit NCCN.org for more information.
Media Contact:
Rachel Darwin
267-622-6624
darwin@nccn.org
Accomplished medical research leader will oversee NCCN programs to advance clinical trials and improve the quality, effectiveness, and accessibility of cancer care.
PLYMOUTH MEETING, Pa., April 9, 2026 /PRNewswire/ -- Today, the National Comprehensive Cancer Network® (NCCN®)—an alliance of leading cancer centers devoted to patient care, research, and education—announced the selection of Nancy L. Lewis, MD, MBS, FACP, as new Chief Scientific Officer (CSO).
Dr. Lewis is an experienced biomedical researcher with expertise in clinical trials for treating solid tumors and hematologic malignancies. She most recently served as Senior Clinical Program Leader for Novartis Pharmaceuticals, after several years as an Associate Professor for various prestigious academic cancer centers. She holds degrees from Penn State University, Temple University School of Medicine, and Rutgers University. Dr. Lewis completed residency at the University of Rochester and Fellowship at Fox Chase Cancer Center—one of NCCN's founding Member Institutions.
"This is a pivotal time for cancer research; there are many successes to build on yet so much still to do. Dr. Lewis is the perfect person to oversee the work we do to foster innovation and knowledge discovery that improves the lives of people with cancer," said Crystal S. Denlinger, MD, CEO, NCCN. "She will be an important asset to our leadership team as she helps us ensure our research and clinical programs continue to advance outcomes in oncology around the world."
Dr. Lewis has previously been honored with awards from some of the foremost cancer organizations across the country, including the American Association for Cancer Research (AACR), The American Society of Clinical Oncology (ASCO), and the American Cancer Society (ACS).
As CSO, Dr. Lewis will assist in the NCCN Oncology Research Program (ORP) as well as key aspects of the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) and NCCN Guidelines for Patients®. She will have oversight of the NCCN Biomarkers Compendium®; NCCN Radiation Therapy Compendium™, and NCCN Imaging Appropriate Use Criteria™. Dr. Lewis will also assist with NCCN's Continuing Medical Education Program and with relevant global and policy initiatives.
"I am thrilled to join the National Comprehensive Cancer Network and contribute to its extraordinary legacy of advancing high‑quality cancer care," said Dr. Lewis. "I look forward to working with NCCN's exceptional collaborators to tackle emerging challenges and drive innovative solutions that improve the lives of patients everywhere."
Dr. Lewis will succeed Dr. Denlinger who previously held the position of CSO before becoming CEO for the organization. Dr. Lewis will assume her new role in May 2026.
About the National Comprehensive Cancer Network
The National Comprehensive Cancer Network® (NCCN®) is a not-for-profit alliance of leading cancer centers devoted to patient care, research, and education. NCCN is dedicated to defining and advancing quality, effective, equitable, and accessible cancer care and prevention so all people can live better lives. The NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) provide transparent, evidence-based, expert consensus-driven recommendations for cancer treatment, prevention, and supportive services; they are the recognized standard for clinical direction and policy in cancer management and the most thorough and frequently-updated clinical practice guidelines available in any area of medicine. The NCCN Guidelines for Patients® provide expert cancer treatment information to inform and empower patients and caregivers, through support from the NCCN Foundation®. NCCN also advances continuing education, global initiatives, policy, and research collaboration and publication in oncology. Visit NCCN.org for more information.
Media Contact:
Rachel Darwin
267-622-6624
darwin@nccn.org
** This press release is distributed by PR Newswire through automated distribution system, for which the client assumes full responsibility. **
Nancy L. Lewis, MD, MBS, FACP, Named New Chief Scientific Officer for National Comprehensive Cancer Network (NCCN)
